Prelude Therapeutics Inc. (PRLD) intrinsic value & 10-year financials
Prelude Therapeutics Inc. (PRLD) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 73.4% a year to $12.1M, with an average return on invested capital of -81.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.26
- Market cap
- $250.9M
- Revenue (FY2025)
- $12.1M
- Revenue growth (8-yr CAGR)
- 73.4%
- ROIC (10-yr avg)
- -81.8%
- Free cash flow (FY2025)
- -$56.4M
PRLD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $12.1M | -$99.5M | -$1.29 | -$56.4M | -861.3% | -114.4% |
| FY2024 | $7.0M | -$127.2M | -$1.68 | -$103.7M | -1995.9% | -77.3% |
| FY2023 | — | -$121.8M | -$2.02 | -$110.6M | — | -53.6% |
| FY2022 | — | -$115.4M | -$2.44 | -$86.7M | — | — |
| FY2021 | — | -$111.7M | -$2.43 | -$85.9M | — | — |
| FY2020 | — | -$56.9M | — | -$46.8M | — | — |
| FY2019 | — | -$27.6M | — | -$26.4M | — | — |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Prelude Therapeutics Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Prelude Therapeutics Inc has historically struggled to out-earn its cost of capital, averaging just -81.8% ROIC.
Prelude Therapeutics Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Prelude Therapeutics Inc is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-42.85 per share.